Featured Research

from universities, journals, and other organizations

Targeted Drug Therapy Found Effective In Patients With Common Form Of Immune-mediated Kidney Disease

Date:
August 18, 2008
Source:
American Society of Nephrology
Summary:
The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a new study. The results suggest that this condition, previously destined to progress to kidney failure in 30-40 percent of cases, can actually be healed in some patients.

The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a new study.

Related Articles


The results suggest that this condition, previously destined to progress to kidney failure in 30-40 percent of cases, can actually be healed in some patients.

Membranous nephropathy (also known as membranous glomerulopathy) is one of the most common immune-mediated kidney diseases, and is thought to be caused by autoimmune reactions against the kidney. The disease, which is characterized by the loss of large amounts of protein in the urine, leads to impaired kidney function that may ultimately require dialysis or renal transplantation.

A variety of immunosuppressive drugs have been tested to inhibit the production of the antibodies that attack the kidneys during the progression of membranous nephropathy, but their effects have been inconsistent. These therapies also can cause significant toxicity and can suppress a patient's immune system, exposing the patient to an increased risk of infections and illnesses.

A new drug called rituximab selectively depletes B lymphocytes, the cells that produce the damaging autoantibodies of membranous nephropathy. The drug was initially developed as a cancer treatment for patients with B cell lymphoma, but kidney researchers have shown that this drug also is safe and reduces the amount of protein lost in the urine due to membranous nephropathy. These same researchers, led by Piero Ruggenenti, MD, of the Negri Bergamo Laboratories in Bergamo, Italy, have now provided evidence that rituximab actually reduces the amount of kidney injury in patients with the disease.

In this study, Dr. Ruggenenti and his colleagues treated 50 patients with membranous nephropathy with rituximab. The investigators found that 10 of the patients eventually achieved a complete remission of their disease, seven of whom provided consent to participate in further evaluations, including additional kidney biopsies. In these patients, deposits of autoantibodies eventually disappeared or were almost entirely reabsorbed and the damage originally noted in certain kidney structures significantly healed.

According to Dr. Ruggenenti, "This represents the first demonstration that kidney injury in membranous nephropathy can regress after selective depletion of B cells. Thus, the present data provide a strong rationale for using rituximab to treat patients with membranous nephropathy."

The authors concluded that their study suggests that the functional and biological abnormalities of membranous nephropathy can be reverted with a safe and selective drug. "Whether this may apply to other [similar kidney conditions] and may translate into long-term protection from renal function loss and the potentially life-threatening complications… remains to be established," they wrote.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Effects of Rituximab on Morphofunctional Abnormalities of Membranous Glomerulopathy. Clinical Journal of the American Society Nephrology, Online August 6, November print issue

Cite This Page:

American Society of Nephrology. "Targeted Drug Therapy Found Effective In Patients With Common Form Of Immune-mediated Kidney Disease." ScienceDaily. ScienceDaily, 18 August 2008. <www.sciencedaily.com/releases/2008/08/080806081445.htm>.
American Society of Nephrology. (2008, August 18). Targeted Drug Therapy Found Effective In Patients With Common Form Of Immune-mediated Kidney Disease. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2008/08/080806081445.htm
American Society of Nephrology. "Targeted Drug Therapy Found Effective In Patients With Common Form Of Immune-mediated Kidney Disease." ScienceDaily. www.sciencedaily.com/releases/2008/08/080806081445.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com
Winter Can Cause Depression — Here's How To Combat It

Winter Can Cause Depression — Here's How To Combat It

Newsy (Nov. 23, 2014) Millions of American suffer from seasonal depression every year. It can lead to adverse health effects, but there are ways to ease symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins